PRISM BioLab Co.,LTD (206A.T)
JPY 244.0
(-4.69%)
JPY 244.0
(-4.69%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.21 Billion JPY | -30.38% |
| 2022 | 1.74 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 3.2 Billion JPY | 3.71% |
| 2024 Q2 | 3.08 Billion JPY | 0.0% |
| 2023 FY | 1.21 Billion JPY | -30.38% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 81.615% |
| GNI Group Ltd. | 62.39 Billion JPY | 98.058% |
| Linical Co., Ltd. | 18.53 Billion JPY | 93.466% |
| Trans Genic Inc. | 9.81 Billion JPY | 87.652% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 78.498% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 82.56% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 79.172% |
| AnGes, Inc. | 28.89 Billion JPY | 95.807% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -39.682% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 99.229% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | 25.155% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | 76.112% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | 72.15% |
| CanBas Co., Ltd. | 2.43 Billion JPY | 50.206% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | 48.958% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 82.52% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | 30.833% |
| Kidswell Bio Corporation | 5.08 Billion JPY | 76.179% |
| PeptiDream Inc. | 67.12 Billion JPY | 98.195% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | 40.634% |
| Ribomic Inc. | 3.54 Billion JPY | 65.849% |
| SanBio Company Limited | 5.04 Billion JPY | 75.998% |
| Healios K.K. | 15.15 Billion JPY | 92.006% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | 1.531% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | 59.833% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | 17.822% |
| StemRIM | 9.08 Billion JPY | 86.658% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 82.391% |
| FunPep Company Limited | 2.49 Billion JPY | 51.371% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | 53.739% |
| Stella Pharma Corporation | 3.82 Billion JPY | 68.292% |
| TMS Co., Ltd. | 3.55 Billion JPY | 65.921% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 79.037% |
| Cuorips Inc. | 6.18 Billion JPY | 80.413% |
| K Pharma,Inc. | 3.31 Billion JPY | 63.444% |
| Takara Bio Inc. | 123.2 Billion JPY | 99.017% |
| ReproCELL Incorporated | 9.05 Billion JPY | 86.618% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | 55.386% |
| StemCell Institute Inc. | 6.54 Billion JPY | 81.485% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 82.666% |
| CellSeed Inc. | 2.46 Billion JPY | 50.87% |